
Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.
The iShares Biotechnology ETF (IBB) surged 26% over three months ending September 4, 2026, outperforming the S&P 500's 4% gain by 22 points. This rally is driven by big pharmaceutical companies acquiring mid- and small-cap biotech firms to offset rev...
